GLA
CBAY

Great Lakes Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Great Lakes Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,105
Closed -$31K – 756
2022
Q1 		$31K Buy
+10,105
New +$31.8K ﹤0.01% 699

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Great Lakes Advisors's CBAY Position: Q2 2022 in Review

Great Lakes Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2022, closing a stake of 10,105 shares — an estimated $31K sold.

Great Lakes Advisors first reported a position in CBAY in Q1 2022 and held it in 1 quarter. The position peaked at $31K in Q1 2022. 106 funds tracked by Wall St. Rank hold CBAY as of Q2 2022.

  • Great Lakes Advisors reported no remaining Cymabay Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Great Lakes Advisors sold 10,105 Cymabay Therapeutics shares in Q2 2022, an estimated $31K.
  • Great Lakes Advisors first reported a position in Cymabay Therapeutics in Q1 2022 and held it in 1 quarter.
  • Great Lakes Advisors's Cymabay Therapeutics position peaked at $31K in Q1 2022.
  • 106 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2022.

Based on Great Lakes Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.